Incidence and impact of COVID-19 in patients with negative Philadelphia myeloproliferative neoplasms - evaluation of late cardiovascular and thrombotic events post-COVID-19

• Grant number: 22/15725-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): February 01, 2023
• Effective date (End): January 31, 2024
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Katia Borgia Barbosa Pagnano
• Grantee: Ana Carolina de Souza Sartti
• Host Institution: Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Myeloproliferative neoplasms (MPN) are clonal diseases from the hematopoietic stem cells, with increased proliferation of the myeloid series (granulocytic, erythrocytic, megakaryocytic series or mast cells) with effective maturation. The mutations involved in the pathogenesis of the classical Philadelphia-negative MPN (polycythemia vera, primary myelofibrosis, and essential thrombocythemia) include JAK2V617F and exon 12, CALR, and MPL W515L/K mutations, which induce constitutive activation of tyrosine kinase. An increased number of thrombotic events have also been observed in COVID-19, a disease caused by the SARS-CoV-2 virus. In addition to respiratory problems, an increase in the incidence of cardiovascular and thrombotic events has been reported in the general population infected by SARS-CoV-2. Despite their different etiology, COVID-19 and MPN share some common mechanisms of activation of coagulation and hypercoagulability. In this way, patients with MPN who are infected by SARS-CoV-2 may have an increased risk of late cardiovascular and thrombotic events; therefore, the long-term support of this population is critical. The present study aims to evaluate the incidence of late cardiovascular and thrombotic events in a cohort of patients with MPN with COVID-19 and compare it to a cohort of patients with MPN who were not infected by SARS-CoV-2.